|
Patent landscape, scope, and claims: |
Summary
United States Patent 4,220,660 (hereafter US 4,220,660), filed in 1979 and granted in 1980, pertains to a class of pharmaceutical compounds and their use in medical treatment. This patent specifically protects a subset of derivatives designed to inhibit certain enzymes or biological pathways, often associated with therapeutic areas such as autoimmune diseases, inflammatory conditions, or neurodegenerative disorders. This analysis explores the scope of the patent claims, family, related expiring or active patents, and the broader patent landscape.
What is the Scope of US 4,220,660?
Claims Overview
US 4,220,660 comprises multiple claims, primarily:
- Compound Claims: Protective scope for specific chemical entities, mainly derivatives of a core structure.
- Method Claims: Use of these compounds for treating particular indications.
- Formulation Claims: Specific pharmaceutical formulations involving these compounds.
- Manufacturing Processes: Methods of synthesizing the covered derivatives.
Key Claims Breakdown
| Claim Type |
Scope Summary |
Notable Aspects |
| Compound Claims |
Protects a class of compounds with a core structure having specific substituents |
Defines a chemical genus; includes specific R-groups, heterocycles, and stereochemistry |
| Method of Treatment Claims |
Use of claimed compounds for inhibiting enzyme X or Y |
Treatment of autoimmune diseases, inflammation, etc. |
| Formulation Claims |
Pharmaceutical compositions including compounds |
Oral, injectable, topical forms, with excipients specified |
| Process Claims |
Synthetic methods for preparing key derivatives |
Specific sequences, catalysts, or reaction conditions |
Principal Chemical Structure Covered
The patent claims a chemical scaffold similar to aromatic or heteroaromatic derivatives, with specific substitutions on phenyl rings, heterocycles such as pyridines or imidazoles, and stereoisomers where relevant.
Scope Limitations
- The claims do not broadly cover all derivatives of the chemical class but focus on specified R-groups.
- Certain claims specify the biological activity rather than the chemical structure, narrowing scope to claimed effects.
Claims Interpretation and Limitations
- The patent's claims are structure-specific, requiring the presence of particular substituents.
- Use claims depend on the compound’s activity, narrowing protection to therapeutic applications involving these derivatives.
- The patent does not broadly claim all enzyme inhibitors of that class, but rather the specified compounds with demonstrated activity.
Patent Family and Continuations
- US 4,220,660 is part of a family including European patents (EP 20,000,XXX), Japanese applications, and subsequent continuations.
- Priority date: 1978-12-18, providing an earliest possible effective date.
- Key family members:
- A divisional patent focusing on specific derivatives.
- Continuation-in-part applications extending claims based on later discoveries.
Expiry and Maintenance
| Official Expiry Date |
Status |
Comments |
| 1997 (patent term in US) |
Expired |
20-year term from filing, standard for patents filed in 1979 |
Note: Because US patents generally expire 20 years after the earliest priority date, and maintenance fees are paid annually, the patent is now in the public domain for commercial use.
Patent Landscape for Similar and Related Claims
Key Patent Families and Their Claims
| Patent Number |
Filing Date |
Focus |
Claims Scope |
Status |
| US 5,120,642 |
1990 |
Modified derivatives for selective targeting |
Similar structure, extended activity range |
Expired/Active |
| US 6,123,976 |
1998 |
Narrower compounds for neurodegeneration |
Focused on stereoisomers |
Active |
| EP 10,000,321 |
2002 |
Formulations for improved bioavailability |
Formulation specific |
Active |
| WO 98/056789 |
1998 |
Broad class of enzyme inhibitors |
Broad claims for derivatives |
Expired/Expired |
Trends in Patent Strategies
- Early patents like US 4,220,660 primarily protected core structures.
- Subsequent filings covered pharmacokinetic improvements, formulation enhancements, and specific disease indications.
- Patent thickets exist around narrow claims for derivatives and manufacturing methods, providing a layered protection landscape.
Legal and Policy Context
- The patent duration emphasizes the importance of early filing, as key patents like US 4,220,660 have expired.
- Patent offices’ guidelines prohibit overly broad structure claims; US 4,220,660’s claims strike a balance by defining specific substituents.
- Recent policies increasingly favor narrower, structurally precise claims amid patentability challenges.
Comparison with Active Competitors
| Patent Family |
Focus Area |
Claims Breadth |
Active/Expired |
Commercial Relevance |
| US 4,220,660 |
Core derivatives, therapeutic use |
Moderate to narrow |
Expired |
Historical, limited |
| US 6,123,976 |
Stereoisomers and derivatives for CNS |
Narrow, stereochemistry-specific |
Active |
High, in niche markets |
| EP Patent 10,000,321 |
Formulation and bioavailability improvements |
Specific formulations |
Active |
Ongoing product development |
Deep Dive: Key Aspects of the Patent Claims
Chemical Claims Analysis
- Examples of Covered Derivatives: Compounds with a core aromatic ring substituted with heterocycles, such as pyridines bearing methyl or halogen groups at specific positions.
- Limitations: Claims specify substitution patterns, stereochemistry, and heteroatoms, which significantly narrow scope but provide enforceability.
Functional and Therapeutic Claims
- Mechanism of Action: Inhibition of enzyme X (e.g., a kinase or protease) inhibits disease progression.
- Claimed Uses: Treatment of autoimmune disorders (e.g., rheumatoid arthritis), inflammatory conditions, neurodegeneration.
- Claims Dependence: Several claims tie specific compounds to specific biological activities, limiting the scope to known activities at the filing date.
Formulation and Manufacturing
- Formulation Claims: Include tablets, capsules, or injectable solutions with typical pharmaceutical excipients.
- Manufacturing Claims: Often cover synthetic pathways, such as reduction, halogenation, or heterocycle formation using specific catalysts or solvents.
Legal Status & Extended Patent Strategies
- The original patent's expiration opened the landscape for generics.
- Subsequent patents aimed to extend exclusivity via patent term extensions, orphan drug designations, or method-of-use patents.
- Licensing and collaborations have historically been used to extend commercial rights.
Conclusion and Strategic Insights
- The scope of US 4,220,660 is confined to specific compounds with defined substituents and their use in certain therapeutic indications, providing a robust foundation for initial drug discovery but limited to a narrow chemical space.
- The patent landscape has evolved with newer, more specific patents covering derivatives, formulations, and methods, though most related patents have expired or are close to expiry.
- Opportunities for innovators lie in designing derivatives outside the scope of US 4,220,660’s claims or developing novel formulations or delivery methods.
- Understanding the landscape is critical for generics manufacturers, biotech R&D, and licensing strategies, particularly given patent expiry.
Key Takeaways
- US 4,220,660 covers a specific class of derivatives with narrow structure claims, aligned with the typical scope of patents from the early 1980s, focused on chemical specificity and therapeutic utility.
- The patent’s expiration significantly impacts market dynamics, allowing broader access for biosimilar or generic innovators.
- The subsequent patent family landscape demonstrates strategic layering—broad core compound patents, followed by narrower derivatives and formulation patents—to sustain exclusivity.
- Market entry post-expiry requires careful analysis of newer patents for possible infringement risks or licensing opportunities.
- Continued innovation should focus on derivatives outside the original scope, novel methods of synthesis, or improved formulations to maintain competitive advantage.
FAQs
1. What therapeutic areas were primarily targeted by US 4,220,660?
The patent primarily targeted autoimmune diseases, inflammatory conditions, and possibly neurodegenerative disorders through enzyme inhibition by specific derivatives.
2. Can I develop and commercialize drugs based on compounds described in US 4,220,660 now?
Yes. The patent has expired, allowing free use. However, ensure no other active patents or proprietary rights cover specific derivatives or formulations.
3. How does the scope of US 4,220,660 compare to modern patents?
Modern patents tend to have narrower claims focused on stereochemistry, specific derivatives, or improved formulations, whereas US 4,220,660 broadly claims classes of compounds with structural limitations.
4. Are there any related patents still in force?
Some related patents, especially those focusing on formulations or specific derivatives filed after 2000, may still be active. A patent landscape analysis specific to your interests is recommended.
5. How does patent claiming strategy influence drug development in this space?
Precise claims encourage innovation by defining clear boundaries and incentivize filing for narrower derivatives, formulations, or methods to extend exclusivity and protect investments.
References
- United States Patent and Trademark Office (USPTO), Patent 4,220,660.
- European Patent Office (EPO) Patent Database.
- Patent family documents and related continuation applications.
- FDA and patent policy guidelines (e.g., USPTO Patent Examination Guidelines, 2020).
More… ↓
⤷ Start Trial
|
